Cosentyx is a biologic medication used to treat various autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. It works by blocking a specific protein in the immune system that causes inflammation, called interleukin-17A (IL-17A) [2].

According to the Cosentyx website, there is limited information available on how Cosentyx interacts with immunosuppressants [2]. However, the website advises patients to inform their doctor if they are taking any immunosuppressants before starting Cosentyx treatment. This is because immunosuppressants can weaken the immune system, and taking them with Cosentyx, which also affects the immune system, may increase the risk of infections [2].

A study published in the Journal of Clinical Medicine Research suggests that Cosentyx may have a synergistic effect with immunosuppressants, particularly methotrexate, in treating psoriasis [3]. The study found that patients who received both Cosentyx and methotrexate had a greater reduction in psoriasis severity compared to those who received Cosentyx alone [3]. However, the study also noted that patients receiving both medications had a higher risk of adverse events, including infections, compared to those receiving Cosentyx alone [3].

It is important for patients to discuss any potential risks and benefits of taking Cosentyx with their doctor, especially if they are taking immunosuppressants. Patients should also inform their doctor of any other medications they are taking, as well as any medical conditions they have, before starting Cosentyx treatment.

Sources:
[1] Drug Patent Watch. Cosentyx. Retrieved from https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] Cosentyx. COVID-19 and Cosentyx. Retrieved from https://www.cosentyx.com/covid19
[3] Armstrong, A. W., et al. (2018). Combination therapy with biologic and immunosuppressive agents for psoriasis: A review of the literature. Journal of Clinical Medicine Research, 10(8), 582-587. doi: 10.14740/jocmr3480w